CareAcross provides personalised support services for patients with cancer. Their focus is on sharing research findings and guidelines, and offer evidence-based approaches to improve quality of life for those living with cancer, whilst strengthening the relationship between the patient and their medical team.
CareAcross engages with thousands of patients diagnosed with many different cancers, providing services around patient engagement, real world evidence, clinical trial recruitment, and patient-reported outcomes.
The relationship between a patient and their doctor is unique, especially when it is about cancer. CareAcross set out to identify the needs and priorities of patients regarding this critical aspect of their experience with cancer.
M3 regularly partners with CareAcross by giving their members the opportunity to take part in our research studies and share their opinion on existing, and future, oncological therapies.
We partnered with CareAcross on this survey which aims to understand the needs of patients affected by different types of cancer.

TAVR matches open-heart surgery durability in low-risk patients, as PARTNER 3 trial seven-year data confirm lasting valve performance.

Mesothelioma trial finds blocking miteochondrial enzym and enzyme in tumour cells controlled disease progression in 67% of patients.

Severe fatty liver disease may be eased as MASH treatment improves gut health, offering a promising new approach beyond the liver.